Hemorrhage in essential thrombocythemia or polycythemia vera: epidemiology, location, risk factors, and lessons learned from the literature
C Nicol, K Lacut, B Pan-Petesch… - Thrombosis and …, 2021 - thieme-connect.com
Hemorrhage is a well-known complication of essential thrombocythemia (ET) and
polycythemia vera (PV), but evidence-based data on its management and prevention are …
polycythemia vera (PV), but evidence-based data on its management and prevention are …
[HTML][HTML] Triple-negative essential thrombocythemia: clinical-pathological and molecular features. A single-center cohort study
D Cattaneo, GA Croci, C Bucelli, S Tabano… - Frontiers in …, 2021 - frontiersin.org
Lack of demonstrable mutations affecting JAK2, CALR, or MPL driver genes within the
spectrum of BCR-ABL1-negative myeloproliferative neoplasms (MPNs) is currently referred …
spectrum of BCR-ABL1-negative myeloproliferative neoplasms (MPNs) is currently referred …
Maternal and fetal outcomes after interferon exposure during pregnancy: a systematic review with meta-analysis
M Zhang, S Fu, D Ren, Y Wu, N Yao, T Ni… - … in Reproductive Health, 2021 - frontiersin.org
Interferon (IFN) treatment is widely applied in viral hepatitis and multiple myeloproliferative
diseases. However, there is considerable controversy on how to deal with unintended …
diseases. However, there is considerable controversy on how to deal with unintended …
Successive development of ischemic stroke and hemorrhagic stroke in a patient with essential thrombocythemia: a case report
X Chen, L Cao, H Feng… - Journal of International …, 2021 - journals.sagepub.com
Patients with essential thrombocythemia (ET) can experience hemorrhagic or ischemic
vascular events. The prevention of these complications is challenging, and the overall risk of …
vascular events. The prevention of these complications is challenging, and the overall risk of …
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort
SC Ranieri, MA Arleo, S Trasarti, L Bizzoni… - … Myeloma and Leukemia, 2021 - Elsevier
Background According to 2008/2016 classification of the World Health Organization (WHO),
a platelet (PLT) count≥ 450× 10 9/L, reduced from the previously published WHO 2001 …
a platelet (PLT) count≥ 450× 10 9/L, reduced from the previously published WHO 2001 …
Maternal and Fetal Outcomes after Interferon Exposure: A Systematic Review and Meta-Analysis
M Zhang, S Fu, D Ren, N Yao, T Ni, Y Feng… - Available at SSRN … - papers.ssrn.com
Background: Interferon (IFN) is widely applied in viral hepatitis and multiple oncologic
diseases. Whereas, there is considerable controversy on how to deal with unintended …
diseases. Whereas, there is considerable controversy on how to deal with unintended …